• 1
    Twelves D, Perkins KS, Counsell C. Systematic review of incidence studies of Parkinson's disease. Mov Disord 2003;18: 1931.
  • 2
    Rajput AH, Offord KP, Beard CM, Kurland LT. Epidemiology of parkinsonism: incidence, classification, and mortality. Ann Neurol 1984;16: 27882.
  • 3
    Sutcliffe RL, Meara JR. Parkinson's disease epidemiology in the Northampton District, England, 1992. Acta Neurol Scand 1995;92: 44350.
  • 4
    Mutch WJ, Dingwall-Fordyce I, Downie AW, et al. Parkinson's disease in a Scottish city. Brit Med J 1986;292: 5346.
  • 5
    Hoehn MM. The natural history of Parkinson's disease in the pre-levodopa and post-levodopa eras. Neurol Clin 1992;10: 3319.
  • 6
    Fahn S. The spectrum of levodopa-induced dyskinesias. Ann Neurol 2000;47(Suppl 1):S211.
  • 7
    Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16: 44858.
  • 8
    Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson's disease? J Neurol Neurosurg Psychiatry 2000;69: 30812.
  • 9
    Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001;56(Suppl 5):S188.
  • 10
    Oertel WH, Quinn NP. Parkinsonism. In: BrandtT, DienerHC, CaplanLR, KennardC, DichgansJ, eds., Neurological Disorders: Course and Treatment. San Diego: Academic Press, 2003.
  • 11
    Rascol O, Goetz C, Koller W, et al. Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet 2002;359: 158998.
  • 12
    Honey C, Gross RE, Lozano AM. New developments in the surgery for Parkinson's disease. Can J Neurol Sci 1999;26(Suppl 2):S4552.
  • 13
    Volkmann J, Allert N, Voges J, et al. Safety and efficacy of pallidal or subthalamic nucleus stimulation in advanced PD. Neurology 2001;56: 54851.
  • 14
    Raiffa H. Decision Analysis: Introductory Lectures on Choices Under Uncertainty. New York: Random House, 1968.
  • 15
    Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 1977;296: 71621.
  • 16
    Weinstein MC, Fineberg HV, Elstein AS, et al. Clinical Decision Analysis. Philadelphia: W.B. Saunders Company, 1980.
  • 17
    Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes (2nd ed.). New York: Oxford University Press, 1997.
  • 18
    Hunink MG, Glasziou PP, Siegel JE, et al. Decision Making in Health and Medicine. Integrating Evidence and Values. Cambridge: Cambridge University Press, 2001.
  • 19
    Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices-Modeling Studies. Value Health 2003;6: 917.
  • 20
    Kurlan R, Clark S, Shoulson I, et al. Economic impact of protective therapy for early Parkinson's disease. Ann Neurol 1988;24: 153.
  • 21
    Siderowf A, Holloway R, Mushlin A. Cost-effectiveness of pallidotomy and add-on medical therapy in advanced Parkinson's disease. Ann Neurol 1998;44: 517.
  • 22
    Smala AM, Berger K, Spottke EA, et al. Cost-effectiveness of cabergoline. Parkinsonism Relat Disord 2001;7(Suppl):S105.
  • 23
    Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
  • 24
    Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996;276: 12538.
  • 25
    Faglioni P, Botti C, Scarpa M, et al. Learning and forgetting processes in Parkinson's disease: a model-based approach to disentangling storage, retention and retrieval contributions. Neuropsychologia 1997;35: 76779.
  • 26
    Faglioni P, Saetti MC, Botti C. Verbal learning strategies in Parkinson's disease. Neuropsychology 2000;14: 45670.
  • 27
    Hsieh S, Hwang WJ, Tsai JJ, Tsai CY. Visuospatial orienting of attention in Parkinson's disease. Percept Mot Skills 1996;82: 130715.
  • 28
    Hsieh S, Hwang WJ, Tsai JJ, Tsai CY. Precued shifting of attention between cognitive sets in Parkinson patients. Psychol Rep 1996;78: 81523.
  • 29
    Sharpe MH. Patients with early Parkinson's disease are not impaired on spatial orientating of attention. Cortex 1990;26: 51524.
  • 30
    El-Deredy W, Branston NM, Samuel M, et al. Firing patterns of pallidal cells in Parkinsonian patients correlate with their pre-pallidotomy clinical scores. Neuroreport 2000;11: 341318.
  • 31
    Reynolds H, Wilson-Barnett J, Richardson G. Evaluation of the role of the Parkinson's disease nurse specialist. Int J Nurs Stud 2000;37: 33749.
  • 32
    Anonymous. A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: design and methods of the CALM-PD Study. Parkinson Study Group. Clin Neuropharmacol 2000;23: 3444.
  • 33
    Hempel AG, Wagner ML, Maaty MA, Sage JI. Pharmacoeconomic analysis of using Sinemet CR over standard Sinemet in parkinsonian patients with motor fluctuations. Ann Pharmacother 1998; 32: 87883.
  • 34
    LeWitt P, Oakes D, Cui L. The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and alpha-tocopherol. Parkinson Study Group. Mov Disord 1997;12: 1839.
  • 35
    Montgomery EB Jr, Lieberman A, Singh G, Fries JF. Patient education and health promotion can be effective in Parkinson's disease: a randomized controlled trial. PROPATH Advisory Board [Comment]. Am J Med 1994;97: 42935.
  • 36
    Martinez-Martin P. An introduction to the concept of ‘quality of life in Parkinson's disease’. J Neurol 1998;245(Suppl 1):S26.
  • 37
    Nuijten MJC. Bridging decision analytic modelling with a cross-sectional study – application to Parkinson's disease. Pharmacoeconomics 2000;17: 22736.
  • 38
    MacMahon DG. Parkinson's disease nurse specialists—an important role in disease management. Neurology 1999;52( Suppl 3):S215.
  • 39
    Spottke EA, Volkmann J, Lorenz D, et al. Evaluation of healthcare utilization and health status of patients with Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus. J Neurol 2002;249: 75966.
  • 40
    Dewey RB, Rao SD, Holmburg SL, Victor RG. Ergotamine/caffeine treatment of orthostatic hypotension in parkinsonism with autonomic failure. Eur J Neurol 1998;5: 5939.
  • 41
    Dodel RC, Eggert K, Oertel WH. Economical research on Parkinson's disease: a review of the literature. Eur J Neurol 1999;6(Suppl 2):S315.
  • 42
    Dodel RC, Spottke EA, Oertel WH. Quality of life and costs of neurosurgical procedures in the treatment of Parkinson's disease. Aktuel Neurol 2000; 27(Suppl 1):S619.
  • 43
    Jost WH. Costs in the treatment of parkinsonism. J Neurol 2000;247(Suppl 4):S313.
  • 44
    Pogarell O, Oertel WH. New dopamine agonists for the treatment of parkinsons-disease. Aktuel Neurol 1998;25: 2029.
  • 45
    Siderowf AD, Holloway RG, Stern MB. Cost-effectiveness analysis in Parkinson's disease: determining the value of interventions. Mov Disord 2000;15: 43945.
  • 46
    Linna M, Taimela E, Apajasalo M, Martilla RJ. Probabilistic sensitivity analysis for evaluating cost-utility of entacapone for Parkinson's disease. Expert Rev Pharmacoeconomics Outcomes Res 2002;2: 917.
  • 47
    Palmer CS, Nuijten MJC, Schmier JK, et al. Cost effectiveness of treatment of Parkinson's disease with entacapone in the United States. Pharmacoeconomics 2002;20: 61728.
  • 48
    Iskedjian M, Einarson TR. Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease. Pharmacoeconomics 2003;21: 11527.
  • 49
    Hoerger TJ, Bala MV, Rowland C, et al. Cost effectiveness of pramipexole in Parkinson's disease in the US. Pharmacoeconomics 1998;14: 54157.
  • 50
    Davey P, Rajan N, Lees M, Aristides M. Cost-effectiveness of pergolide compared to bromocriptine in the treatment of Parkinson's disease: a decision-analytic model. Value Health 2001;4: 30815.
  • 51
    Nuijten MJC, Van Iperen P, Palmer CS, et al. Cost-effectiveness analysis of entacapone in Parkinson's disease: a Markov process analysis. Value Health 2001;4: 31628.
  • 52
    Tomaszewski KJ, Holloway RG. Deep brain stimulation in the treatment of Parkinsons's disease. A cost-effectiveness analysis. Neurology 2001;57: 66371.
  • 53
    Shimbo T, Hira K, Takemura M, Fukui T. Cost-effectiveness analysis of dopamine agonists in the treatment of Parkinson's disease in Japan. Pharmacoeconomics 2001;19: 87586.
  • 54
    Hawthorne G, Richardson J. Measuring the value of program outcomes: a review of multiattribute utility measures. Expert Rev Pharmacoeconomics Outcomes Res 2001;1: 21528.
  • 55
    Mitchell SL, Harper DW, Lau A, Bhalla R. Patterns of outcome measurement in Parkinson's disease clinical trials. Neuroepidemiology 2000;19: 1008.
  • 56
    Fahn S, Elton RL. Members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: FahnS, MarsdenCD, CalneDB, GoldsteinM, eds., Recent Developments in Parkinson's Disease II. New York: Macmillan, 1987.
  • 57
    Schrag A, Jahanshahi M, Quinn N. How does Parkinson's disease affect quality of life? A comparison with quality of life in the general population. Mov Disord 2000;15: 111218.
  • 58
    Dodel RC, Singer M, Köhne-Volland R, et al. The economic impact of Parkinson's disease. An estimation based on a 3-month prospective analysis. Pharmacoeconomics 1998;14: 299312.
  • 59
    LePen C, Wait S, Moutard-Martin F, et al. Cost of illness and disease severity in a cohort of French patients with Parkinson's disease. Pharmacoeconomics 1999;16: 5969.
  • 60
    Di Rocco A, Molinari SP, Kollmeier B, Yahr MD. Parkinson's disease: progression and mortality in the L-DOPA era. Adv Neurol 1996;69: 311.
  • 61
    Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967;17: 42742.
  • 62
    Riederer P, Sian J, Gerlach M. Is there neuroprotection in Parkinson syndrome? J Neurol 2000; 247(Suppl 4):S811.
  • 63
    Wermuth L, Stenager EN, Boldsen J. Mortality in patients with Parkinson's disease. Acta Neurol Scand 1995;92: 558.
  • 64
    Treves TA, Pedro-Cuesta JD. Parkinsonism mortality in the US, 1. Time and space distribution. Acta Neurol Scand 1991;84: 38997.
  • 65
    Foltynie T, Brayne C, Barker RA. The heterogeneity of idiopathic Parkinson's disease. J Neurol 2002;249: 13845.
  • 66
    Poewe W, Gerstenbrand F. Klinische Klassifikation des Parkinson-Syndroms-Subtypen und Übergänge zu Multi-System-Atrophien. In: SchnabertG, AuffE, eds., Das Parkinson-Syndrom. Frankfurt: Editiones Roche, 1986.
  • 67
    Kuntz KM, Goldie SJ. Assessing the sensitivity of decision-analytic results to unobserved markers of risk: defining the effects of heterogeneity bias. Med Decis Making 2002;22: 21827.
  • 68
    Siebert U, Goldie SJ, Kuntz KM. Pharmacogenomics-Bias. Simulationen zur Fehlbeurteilung von Arzneimitteleffekten bei Nichtberücksichtigung genetischer Heterogenität (Abstract). 47th Annual Meeting of the German Society for Medical Informatics, Biometry, and Epidemiology (GMDS). Berlin, Germany, 2002.
  • 69
    Doubilet P, Begg CB, Weinstein MC, et al. Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med Decis Making 1985;5: 15777.
  • 70
    Weinstein MC, Toy EL, Sandberg EA, et al. Modeling for health care and other policy decisions: uses, roles, and validity. Value Health 2001;4: 34861.
  • 71
    Buxton MJ, Drummond MF, Van Hout BA, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 1997;6: 21727.
  • 72
    Anonymous. Decision analytic modelling in the economic evaluation of health technologies. A consensus statement. Consensus Conference on Guidelines on Economic Modelling in Health Technology Assessment. Pharmacoeconomics 2000; 17: 4434.
  • 73
    Siebert U. When should decision-analytic modeling be used in the economic evaluation of health care? Eur J Health Econ 2003;4: 14350.